Dyslipidemia market is a condition in which the levels of lipids (cholesterol, triglycerides, or both) or low high-density lipoprotein (HDL) cholesterol level elevated due to multiple reasons including lifestyle, genetics-disorders, drugs etc.
According to World Health Organization, there were approximately 17.9 million people in 2016, who died from cardiovascular diseases, almost more than half of these cases could have been avoided with the availability of proper medical treatment. This significant number is expected to act as a driver to the market growth.
Dyslipidemia market is expected to rise gradually to an estimated value of USD 27.52 billion by 2026, registering a CAGR of 10.50% in the forecast period of 2019-2026 with the annual sales of USD 12.38 billion in the year of 2018. This rise in market value can be attributed to the increase in prevalence and awareness along with concerns regarding the health of patients.
Market Drivers and Restraints:
Increase in global geriatric population
Increase in prevalence of lifestyle diseases
Rise in acceptance of telemental health
Increase in availability of generic drugs
Lack of R&D initiatives in this area.
patent expiry for some blockbuster drugs
Fewer Government initiatives taken in this direction.
The major players covered in the Dyslipidemia Market
Few of the major competitors currently working in the Dyslipidemia market are AstraZeneca (UK), Merck, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis, Cipla Inc., CJ HealthCare, CKD Bio, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, JW Pharmaceuticals, Kadmon Pharmaceuticals, Lupin Pharmaceuticals and few among others.
Major TOC Of The Report
Chapter One: Dyslipidemia Market Overview
Chapter Two: Manufacturers Profiles
Chapter Three: Global Dyslipidemia Market Competition, by Players
Chapter Four: Global Dyslipidemia Market Size by Regions
Chapter Five: North America Dyslipidemia Market Revenue by Countries
Chapter Six: Europe Dyslipidemia Market Revenue by Countries
Chapter Seven: Asia-Pacific Dyslipidemia Market Revenue by Countries
Chapter Eight: South America Dyslipidemia Market Revenue by Countries
Key Report Highlights
Comprehensive pricing analysis based on different product types and regional segments
Market size data in terms of revenue and sales volume
Deep insights about regulatory and investment scenarios of the global Dyslipidemia Market
Analysis of market effect factors and their impact on the forecast and outlook of the global Dyslipidemia Market
The detailed assessment of the vendor landscape and leading companies to help understand the level of competition in the global Dyslipidemia Market
A roadmap of growth opportunities available in the global Dyslipidemia Market with the identification of key factors
The exhaustive analysis of various trends of the global Dyslipidemia Market to help identify market developments
Key Questions Answered in Report:
What is the key to the Dyslipidemia Market?
What will the Dyslipidemia Market Demand and what will be Growth?
What are the latest opportunities for Dyslipidemia Market in the future?
What are the strengths of the key players?
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email:
[email protected]